Giuliana Grossi

A cohort study aimed to examine the risk of overdose when treating patients with benzodiazepines compared with alternative therapies for sleep disorders, specifically in young people.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

The burden of sleep disorders is high among the transgender or gender-nonconforming population and this study evaluated the role of gender-affirming therapy on that relationship.

Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.

A study published in Diabetologia discovered that individuals who are exposed to high light pollution while they sleep show a greater risk of developing type 2 diabetes.

Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.

Sleep Medicine Expert Daniel Gottlieb, MD, MPH, details a response to the USPSTF screening recommendations for obstructive sleep apnea in a primary care setting.

US Prevention Services Task Force (USPSTF) announces that after reviewing the clinical utility of obstructive sleep apnea screening tools in a primary care setting, there's insufficient evidence to determine the balance between benefit and harm.

Cognitive Behavioral Therapy (CBT) for insomnia is the front-line treatment for sleep disturbance. However, the effectiveness of this approach for those with primary brain tumors hasn't been evaluated until now.

"Having the ability to enhance the sleep quality in a way that is scientifically important, and also taking into account objective measurements opens a lot of possibilities," Gary Garcia-Molina, PhD, said in an interview.

Because unhealthy sleep is associated with multiple conditions and higher risk of mortality, investigators call for further research on the potential to optimize overall sleep health in the US.

Gary Garcia-Molina, PhD, explains precisely how Sleep Number smart bed technology works after conducting multiple sleep studies.

Nonprofit organizations combined efforts to plan a meeting to inform and educate the FDA and key stakeholders about the experience of caregivers and patients with Phelan-McDermid syndrome (PMS).

At the International Pediatric Sleep Association (IPSA) Congress 2022, investigators from Sleep Number presented 2 investigations that utilized its smart bed technology to analyze pediatric sleep behaviors.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

New data from the International Pediatric Sleep Association (IPSA) Congress 2022 used smart bed technology that revealed consistent findings to previous studies.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

Aside from the inability to fulfill the site inspection, there was no other reason for the FDA deferral. The approval of the combination drug candidate's 2 components are still expected.

The Pompe disease community is anticipating the pivotal FDA decision for AT-GAA, a combination therapy for late-onset Pompe disease (LOPD) that has the potential to expand the armamentarium of physicians.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

Depressive disorders are often accompanied by low levels of resilience and research indicates that targeting insomnia symptoms could address the severity of these psychiatric disorders.

The common inherited condition autosomal dominant polycystic kidney disease (ADPKD) remains elusive when presented in primary care due to its nonspecific symptoms.

Investigators are urging for more research on the mechanisms involved with comorbid insomnia and obstructive sleep apnea (OSA) to reduce the mortality risk in patients with both sleep disorders.

Iptacopan has the potential to address an unmet need in PNH by significantly increasing hemoglobin levels in patients who remain anemic, fatigued and dependent on blood transfusions after anti-C5 treatment.

The moisturizer was designed to address concerns regarding the suitability of sunscreens for individuals with skin of color and show the importance of "aesthetic elegance” to increase sunscreen utilization.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.